After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

The use of probiotics by cancer patients is increasing, including among those undergoing
immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …

BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …